Eli Lilly’s ongoing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, extended through October 2026, continues in the joint research phase without any announced commercial license or technology transfer. This setup limits Lilly to internal R&D assessment of the ultrasonic spray-dried formulation for long-acting peptides, leaving insufficient time and no public milestones to trigger a full deal before the October 7 resolution. Lilly’s parallel moves, including a June 2025 Camurus FluidCrystal partnership for incretin therapies and a 2026 Nimbus oral obesity collaboration, further signal preference for alternative delivery systems, sustaining trader consensus around the 63% No probability.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于最新
最新
2026-10-07
最新
最新
2026-10-07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, extended through October 2026, continues in the joint research phase without any announced commercial license or technology transfer. This setup limits Lilly to internal R&D assessment of the ultrasonic spray-dried formulation for long-acting peptides, leaving insufficient time and no public milestones to trigger a full deal before the October 7 resolution. Lilly’s parallel moves, including a June 2025 Camurus FluidCrystal partnership for incretin therapies and a 2026 Nimbus oral obesity collaboration, further signal preference for alternative delivery systems, sustaining trader consensus around the 63% No probability.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市场开放时间： May 5, 2026, 8:02 PM ET
交易量
$8,471结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, extended through October 2026, continues in the joint research phase without any announced commercial license or technology transfer. This setup limits Lilly to internal R&D assessment of the ultrasonic spray-dried formulation for long-acting peptides, leaving insufficient time and no public milestones to trigger a full deal before the October 7 resolution. Lilly’s parallel moves, including a June 2025 Camurus FluidCrystal partnership for incretin therapies and a 2026 Nimbus oral obesity collaboration, further signal preference for alternative delivery systems, sustaining trader consensus around the 63% No probability.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$8,471结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, extended through October 2026, continues in the joint research phase without any announced commercial license or technology transfer. This setup limits Lilly to internal R&D assessment of the ultrasonic spray-dried formulation for long-acting peptides, leaving insufficient time and no public milestones to trigger a full deal before the October 7 resolution. Lilly’s parallel moves, including a June 2025 Camurus FluidCrystal partnership for incretin therapies and a 2026 Nimbus oral obesity collaboration, further signal preference for alternative delivery systems, sustaining trader consensus around the 63% No probability.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题